A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies (NCT00781612)
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
🩺 Plain-English Summary (8th-Grade Level)
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (179 Sites)
Showing the first 25 of 179 sites.
- City of Hope National Medical Center — Duarte, California
- Can Care Assoc Med Group Inc — Redondo Beach, California
- Univ of Calif, San Francisco — San Francisco, California
- Central Coast Medical Oncology — San Luis Obispo, California
- UCLA Oncology Office — Santa Monica, California
- Stanford Cancer Institute — Stanford, California
- Kaiser Permanente - Walnut Creek — Walnut Creek, California
- Univ of Colorado Canc Ctr — Aurora, Colorado
- University of Colorado — Aurora, Colorado
- Rocky Mountain Cancer Center - Denver — Denver, Colorado
- Christina Care Institutional Review Board — Newark, Delaware
- Florida Cancer Specialists — Fort Myers, Florida
- Memorial Cancer Institute at Memorial West — Pembroke Pines, Florida
- Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building) — St. Petersburg, Florida
- Florida Cancer Specialists - Tampa (Dr. MLK Blvd) — Tampa, Florida
- Northwest Georgia Oncology Centers PC - Marietta — Marietta, Georgia
- Kootenai Cancer Center — Post Falls, Idaho
- Loyola University Med Center — Maywood, Illinois
- Illinois Cancer Care — Peoria, Illinois
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Hematology-Oncology — Bettendorf, Iowa
- Oncology Assoc of Cedar Rapids — Cedar Rapids, Iowa
- Anne Arundel Medical Center — Annapolis, Maryland
- Johns Hopkins Univ Med Center — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasm Metastasis
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) — Birmingham, Alabama
- Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases — Detroit, Michigan
Explore by condition: All Neoplasm Metastasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.